SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________



FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

________________

 


Date of Report (Date of earliest event reported):
June 29, 2006

Alpharma Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of incorporation)

1-8593
(Commission File
Number)

22-2095212
(IRS Employer Identification)

 

One Executive Drive, Fort Lee, New Jersey 07024
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code
(201) 947-7774

 
 

Not Applicable

______________________________________________
(Former name or former address, if changed since

last report)

 

 

Item 1.01. Entry Into A Material Definitive Agreement

On June 29, 2006, Alpharma Inc. (the "Company") and Ingrid Wiik amended and restated her employment agreement ("Agreement") to set forth terms related to her retirement as President and Chief Executive Officer of the Company on June 30, 2006. Ms. Wiik will continue to serve as a member of the Company's board of directors. The key terms of the Agreement are as follows:

 

On July 4. 2006, Alpharma AS, a wholly owned subsidiary of the Company, and A.L. Industrier ASA ("ALI") entered into an amendment to the existing Administrative Services Agreement between the parties (the "Services Agreement"), pursuant to which the Services Agreement was extended through December 31, 2006 for an additional services fee of NOK 200,000 (approximately $32,000). ALI is the beneficial owner of all the shares of the Company's Class B common stock. As a result, the Company considers all agreements between ALI and the Company (or its subsidiaries) to be material.

The foregoing descriptions of the Agreement and the Services Agreement do not purport to be complete and are qualified in their entirety by the terms and conditions of the respective agreements (which are attached as Exhibits hereto).

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(b) On June 29, 2006, Einar Sissener informed the Company's Board of Directors, that he is retiring as a Class B Director, as of June 29.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

10.1

Second Addendum to Administrative Services Agreement, dated July 4, 2006, between A.L. Industrier ASA and Alpharma AS is filed as an Exhibit to this Report.

   

10.2

Amended and Restated Employment Agreement, dated June 29, 2006, between Alpharma Inc and Ingrid Wiik is filed as an Exhibit to this Report.


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ALPHARMA INC.


 

By: /s/ Robert F. Wrobel

 

Name: Robert F. Wrobel

Title: Executive Vice President and CLO

Date: July 6, 2006